Evaluation of proliferative activity of the dipeptide mimetics of the 1st, 2nd and 4th loops of the brain-derived neurotrophic factor in vitro
https://doi.org/10.37489/2587-7836-2025-3-9-12
EDN: CYYCGD
Abstract
The purpose of this work was to study the effect of dimeric dipeptide mimetics of the 1st, 2nd and 4th loops of BDNF – GSB-214 (heptamethylenediamide bis-monosuccinyl-methionyl-serine), GTS-201 (hexamethylenediamide bis-hexanoyl-seryl-lysine) and GSB-106 (hexamethylenediamide bis-monosuccinylseryl-lysine) on the proliferation of the HT-22 hippocampal cells using MTT-assay. It has been established that the mimetics of the 1st, 2nd and 4th loops of BDNF after incubation with HT-22 cells for 48 and 72 hours did not affect their proliferative activity.
About the Authors
I. O. Logvinov
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Ilya O. Logvinov — Research Scientist Molecular pharmacology laboratory
Moscow
S. V. Nikolaev
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Sergey V. Nikolaev — Research Scientist Molecular pharmacology laboratory
Moscow
T. A. Antipova
Federal research center for innovator and emerging biomedical and pharmaceutical technologies
Russian Federation
Russian Federation
Tatyana A. Antipova — PhD, Cand. Sci. (Biology), Leading researcher, Molecular pharmacology laboratory
Moscow
References
1. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009 Jun;5(6):311-22. doi: 10.1038/nrneurol.2009.54.
2. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressantlike effects in cellular and behavioral models. Neuropsychopharmacology. 2010 Nov;35(12):2378-91. doi: 10.1038/npp.2010.114.
3. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010 Apr;70(5):289-97. doi: 10.1002/dneu.20758.
4. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999 Apr 22;52(7):1427-33. doi: 10.1212/wnl.52.7.1427.
5. Poduslo JF, Curran GL. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar;36(2):280-6. doi: 10.1016/0169-328x(95)00250-v.
6. Gudasheva TA, Tarasyuk AV, Pomogaibo SV, et al. Design and synthesis of dipeptide mimetics of brain-derived neurotrophic factor. Russian Journal of Bioorganic Chemistry. 2012;38(3):280-290. (In Russ.). doi: 10.1134/S1068162012030053.
7. Gudasheva TA, Tarasiuk AV, Sazonova NM, et al. A novel dimeric dipeptide mimetic of the BDNF selectively activates the MAPK-Erk signaling pathway. Doklady Biochemistry and Biophysics. 2017;47(1):291-295. (In Russ.). doi: 10.7868/S0869565217250235.
8. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003 Apr;4(4):299-309. doi: 10.1038/nrn1078.
9. Davis JB, Maher P. Protein kinase C activation inhibits glutamateinduced cytotoxicity in a neuronal cell line. Brain Res. 1994 Jul 25;652(1):169-73. doi: 10.1016/0006-8993(94)90334-4
Review
For citations:
Logvinov I.O., Nikolaev S.V., Antipova T.A. Evaluation of proliferative activity of the dipeptide mimetics of the 1st, 2nd and 4th loops of the brain-derived neurotrophic factor in vitro. Pharmacokinetics and Pharmacodynamics. 2025;(3):9-12. (In Russ.) https://doi.org/10.37489/2587-7836-2025-3-9-12. EDN: CYYCGD
Views:
28
Email this article 